The cardiovascular system is where anabolic-androgenic steroids (AAS) exact their most serious and best-documented long-term toll. It is also the area users most often ignore, because the changes are usually silent until something goes wrong. This guide lays out the four main cardiac costs with the numbers behind them, and what monitoring is worth doing.

Lipids: the fastest and most dramatic change Oral AAS in particular wreck the lipid profile, and they do it quickly. The mechanism is upregulation of hepatic lipase and suppression of the liver's handling of cholesterol. In controlled studies, supraphysiological androgens can drop HDL ('good' cholesterol) by 40-70% and raise LDL ('bad' cholesterol) substantially, sometimes within a couple of weeks. A study of stanozolol reported HDL falling by roughly half at moderate oral doses; injectable testosterone is generally gentler than 17-alpha-alkylated orals but still moves lipids in the wrong direction dose-dependently. An HDL in the single digits is not unusual on aggressive oral cycles. This shift is pro-atherogenic — it accelerates plaque formation — and it is the change most consistently seen across the whole class.

Blood pressure AAS raise blood pressure through fluid and sodium retention (estrogenic compounds especially), increased red-cell mass thickening the blood, and direct vascular effects. Meaningful rises of roughly 8-10 mmHg systolic are commonly reported, and long-term users show measurably higher rates of hypertension than non-users. Sustained high blood pressure is itself a driver of the heart-muscle thickening discussed below, so it is not a cosmetic bloat issue — it is a load on the heart. - The two blood-pressure-friendly management drugs commonly discussed are telmisartan, an angiotensin-receptor blocker that also has favourable metabolic effects, and nebivolol, a beta-blocker with a vasodilating (nitric-oxide) action. Both address the number, not the underlying androgen load.

Hematocrit and the donation question Androgens stimulate erythropoiesis, raising red-cell count, hemoglobin and hematocrit. Hematocrit climbing into the mid-50s percent, or higher, is common on cycle (normal male range is roughly 41-50%). Thicker blood raises viscosity and, at least in theory and in some clinical data, the risk of clotting events. The traditional response is therapeutic phlebotomy or blood donation to bring hematocrit down. Two caveats worth knowing: - Repeated donation drives down ferritin (iron stores), and iron-deficient erythropoiesis can paradoxically make blood-cell quality worse; do not donate reflexively without checking iron. - Some recent thinking holds that a modestly elevated hematocrit driven purely by androgens may be less thrombotic than the same number in, say, polycythemia vera, and that aggressive phlebotomy is over-used. The honest position is that this is debated; a hematocrit above the mid-50s is still worth addressing, ideally guided by symptoms and a doctor rather than a fixed cut-off.

Cardiac structure: LVH and reduced function This is the most concerning long-term finding and the hardest to reverse. Chronic AAS use is associated with left ventricular hypertrophy (LVH) — thickening of the heart's main pumping chamber — and, more importantly, with impaired diastolic function (the heart's ability to relax and fill between beats) and reduced ejection fraction. The landmark study here is Baggish and colleagues (Circulation, 2017), which used echocardiography in long-term AAS users versus non-using weightlifters and found the users had significantly lower left-ventricular systolic function and worse diastolic function, plus far more coronary plaque on CT. Cumulative lifetime dose tracked with the severity of the plaque burden. Some of the structural change is thought to partly regress after cessation, but coronary plaque does not simply disappear, and cases of premature cardiomyopathy and sudden cardiac death in long-term users are well documented.

How the compound class changes the picture Not all AAS hit the heart equally. Oral 17-alpha-alkylated compounds (stanozolol, oxandrolone, methandrostenolone and similar) are the harshest on lipids because they pass through the liver and strongly induce hepatic lipase. Injectable testosterone esters are comparatively gentler but still move lipids, blood pressure and hematocrit dose-dependently. Non-aromatizing 19-nors such as trenbolone do not drive estrogenic fluid retention but are frequently reported to raise blood pressure and worsen lipids markedly, and nandrolone raises hematocrit reliably. The practical implication: dose, oral-versus-injectable, and duration matter more for cardiac risk than which specific brand of compound you pick.

What monitoring actually helps Monitoring does not neutralise the risk, but it catches the dangerous trajectories early: - Lipid panel before, during and after a cycle. If HDL/LDL are badly deranged, that is a reason to reconsider dose, drop orals, or come off — not just to add fish oil. - Blood pressure at home regularly, not once a year at a clinic. Treat it if it stays elevated. - Complete blood count for hematocrit/hemoglobin, plus ferritin if you are donating. - A baseline and periodic echocardiogram for anyone using long-term; it is the only way to see LVH and diastolic dysfunction before symptoms appear. A coronary calcium/CT angiogram gives a picture of plaque for higher-risk or older users.

Bottom line The cardiovascular cost of AAS is real, measurable and dose-dependent: HDL can fall by half or more, blood pressure rises, hematocrit climbs into a range that thickens the blood, and long-term users carry more coronary plaque and worse heart function than their drug-free peers. Ancillaries like telmisartan and nebivolol manage the numbers, and phlebotomy manages hematocrit, but none of them undo the underlying damage. The only things that truly lower cardiovascular risk are lower doses, fewer orals, more time off, and monitoring that actually changes what you do.